As another clinical trial of a mitochondria-targeting cancer therapy faces failure, it calls for a thorough re-evaluation of the strategy; the time has come to go from the bedside back to the bench.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Pan-tissue mitochondrial phenotyping reveals lower OXPHOS expression and function across cancer types
Scientific Reports Open Access 05 October 2023
-
Preventing mitochondrial reverse electron transport as a strategy for cardioprotection
Basic Research in Cardiology Open Access 28 August 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Stine, Z. E., Schug, Z. T., Salvino, J. M. & Dang, C. V. Nat. Rev. Drug Discov. 21, 141–162 (2022).
Vasan, K., Werner, M. & Chandel, N. S. Cell Metab. 32, 341–352 (2020).
Gorelick, A. N. et al. Nat. Metab. 3, 558–570 (2021).
Yap, T. A. et al. Nat. Med. https://doi.org/10.1038/s41591-022-02103-8 (2023).
Molina, J. R. et al. Nat. Med. 24, 1036–1046 (2018).
Alistar, A. et al. Lancet Oncol. 18, 770–778 (2017).
Yen, K. et al. Cancer Discov. 7, 478–493 (2017).
Wolpaw, A. J. & Dang, C. V. Trends Cell Biol. 28, 201–212 (2018).
Leone, R. D. et al. Science 366, 1013–1021 (2019).
Buck, M. D., Sowell, R. T., Kaech, S. M. & Pearce, E. L. Cell 169, 570–586 (2017).
Pilon-Thomas, S. et al. Cancer Res. 76, 1381–1390 (2016).
Gong, Y. et al. Cancer Res. Commun. 2, 842–856 (2022).
Acknowledgements
C.V.D. is supported by the Ludwig Institute for Cancer Research and National Cancer Institute (NCI) grants R01CA252225, R01CA054197 and R01CA057341.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
C.V.D. is consultant for the Barer Institute, Rafael Holdings, Inc. X.Z. declares no competing interests.
Rights and permissions
About this article
Cite this article
Zhang, X., Dang, C.V. Time to hit pause on mitochondria-targeting cancer therapies. Nat Med 29, 29–30 (2023). https://doi.org/10.1038/s41591-022-02129-y
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-022-02129-y
This article is cited by
-
The immunometabolic ecosystem in cancer
Nature Immunology (2023)
-
Pan-tissue mitochondrial phenotyping reveals lower OXPHOS expression and function across cancer types
Scientific Reports (2023)
-
Crosstalk between oxidative phosphorylation and immune escape in cancer: a new concept of therapeutic targets selection
Cellular Oncology (2023)
-
Preventing mitochondrial reverse electron transport as a strategy for cardioprotection
Basic Research in Cardiology (2023)